Tier 2 — strong

A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects

Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde-Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N
The American journal of clinical nutrition 2018 108; 2; 343-353

Bibliography

PubMed
PMID 29992272
DOI
10.1093/ajcn/nqy132
Funding
Funding details are not specified in the accessible publication information.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignRandomized placebo-controlled human trial
ModelHuman participants
Sample40 sedentary men with obesity and insulin resistance
InterventionNR 1000 mg twice daily versus placebo
Duration12 weeks
EndpointsClamp insulin sensitivity; glucose metabolism; body composition

What the study showed, in plain terms

NR did not improve insulin sensitivity, glucose handling, energy expenditure or body composition in this randomized trial.

Key findings

No serious adverse events attributed to NR were observed.

What this study can and cannot tell us

A specific male population and limited duration; the null metabolic results should not be replaced by favorable animal findings.

Related papers in the corpus

Tier 2
Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity
Dollerup OL et al. · The Journal of clinical endocrinology and metabolism · 2019
Tier 2
Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men
Dollerup OL et al. · The Journal of physiology · 2020
Tier 2
Oral supplementation of nicotinamide riboside alters intestinal microbial composition in rats and mice, but not humans
Peluso AA et al. · npj aging · 2023
Tier 2
Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans
Remie CME et al. · The American journal of clinical nutrition · 2020

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology